Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.

Baussano I, Lazzarato F, Ronco G, Dillner J, Franceschi S.

Int J Cancer. 2013 Oct 15;133(8):1876-81. doi: 10.1002/ijc.28197. Epub 2013 May 15.

2.

The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.

Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH.

Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):459-66.

3.

Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?

Bonanni P, Gabutti G, Demarteau N, Boccalini S, La Torre G.

BMC Infect Dis. 2015 Sep 17;15:377. doi: 10.1186/s12879-015-1067-9.

4.

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.

Vaccine. 2008 Jul 29;26(32):4080-93. doi: 10.1016/j.vaccine.2008.04.053. Epub 2008 May 15.

PMID:
18550229
5.
6.

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.

Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ.

Br J Cancer. 2008 Jul 22;99(2):230-8. doi: 10.1038/sj.bjc.6604462. Epub 2008 Jul 8.

7.

Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.

Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.

Vaccine. 2015 May 7;33 Suppl 1:A167-73. doi: 10.1016/j.vaccine.2014.12.067.

PMID:
25919157
8.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
9.

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G.

Sex Health. 2007 Sep;4(3):165-75.

PMID:
17931529
10.

Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs.

Elfström KM, Lazzarato F, Franceschi S, Dillner J, Baussano I.

J Infect Dis. 2016 Jan 15;213(2):199-205. doi: 10.1093/infdis/jiv368. Epub 2015 Jul 3.

PMID:
26142436
11.

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.

Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R.

BMC Med. 2011 May 12;9:54. doi: 10.1186/1741-7015-9-54.

12.

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary.

Vokó Z, Nagyjánosi L, Kaló Z.

BMC Public Health. 2012 Oct 30;12:924. doi: 10.1186/1471-2458-12-924.

13.

Health and economic implications of HPV vaccination in the United States.

Kim JJ, Goldie SJ.

N Engl J Med. 2008 Aug 21;359(8):821-32. doi: 10.1056/NEJMsa0707052.

14.

Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

PLoS One. 2014 Mar 20;9(3):e89974. doi: 10.1371/journal.pone.0089974. eCollection 2014.

15.

Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.

Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ.

J Infect Dis. 2015 Jan 15;211(2):206-15. doi: 10.1093/infdis/jiu413. Epub 2014 Jul 23.

16.

Cost-effectiveness of human papilloma virus vaccination in Iceland.

Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.

Acta Obstet Gynecol Scand. 2009;88(12):1411-6. doi: 10.3109/00016340903322750.

PMID:
19900074
17.

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M.

Vaccine. 2008 Oct 16;26(44):5654-61. doi: 10.1016/j.vaccine.2008.07.098. Epub 2008 Aug 22.

PMID:
18723068
18.

HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness.

Coupé VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J.

Int J Cancer. 2009 Feb 15;124(4):970-8. doi: 10.1002/ijc.24000.

19.

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.

Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J.

BMC Cancer. 2013 Jan 8;13:10. doi: 10.1186/1471-2407-13-10.

20.

Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).

Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M.

Vaccine. 2013 Dec 30;31 Suppl 6:G65-77. doi: 10.1016/j.vaccine.2012.06.096.

PMID:
24331822
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk